L.M. Kohn & Company Pfizer Inc Transaction History

L.M. Kohn & Company

$390 Million
Q3 2024

A detailed history of L.M. Kohn & Company transactions in Pfizer Inc stock. As of the latest transaction made, L.M. Kohn & Company holds 36,314 shares of PFE stock, worth $937,990. This represents 0.27% of its overall portfolio holdings.

Number of Shares

36,314

Previous 31,740 14.41%

Holding current value

$937,990

Previous $888,000 18.24%

% of portfolio

0.27%

Previous 0.24%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$27.7 - $31.39 $126,699 - $143,577	4,574 Added 14.41%	36,314 $1.05 Million
Q2 2024 Jul 30, 2024	SELL	$25.26 - $29.6 $43,901 - $51,444	-1,738 Reduced 5.19%	31,740 $888,000
Q1 2024 Apr 25, 2024	BUY	$25.89 - $29.73 $39,119 - $44,922	1,511 Added 4.73%	33,478 $929,000
Q4 2023 Feb 09, 2024	BUY	$26.13 - $33.94 $82,701 - $107,420	3,165 Added 10.99%	31,967 $920,000
Q3 2023 Nov 06, 2023	BUY	$32.09 - $37.51 $144,501 - $168,907	4,503 Added 18.53%	28,802 $955,000
Q2 2023 Aug 08, 2023	SELL	$36.12 - $41.79 $12,750 - $14,751	-353 Reduced 1.43%	24,299 $891,000
Q1 2023 May 08, 2023	SELL	$39.39 - $51.28 $18,592 - $24,204	-472 Reduced 1.88%	24,652 $1.01 Million
Q4 2022 Feb 08, 2023	BUY	$41.75 - $54.5 $44,589 - $58,206	1,068 Added 4.44%	25,124 $1.29 Million
Q3 2022 Oct 19, 2022	BUY	$43.76 - $53.42 $87 - $106	2 Added 0.01%	24,056 $1.05 Million
Q2 2022 Aug 05, 2022	BUY	$46.53 - $55.17 $65,700 - $77,900	1,412 Added 6.24%	24,054 $1.26 Million
Q1 2022 May 25, 2022	BUY	$45.75 - $56.69 $1.04 Million - $1.28 Million	22,642 New	22,642 $1.17 Million

Others Institutions Holding PFE

# of Institutions

3,258

Shares Held

3.62B

Call Options Held

77.2M

Put Options Held

122M

View Full List

About PFIZER INC

Ticker PFE
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 5,612,349,952
Market Cap $145B
Description
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...

More about PFE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of L.M. Kohn & Company, based on Form 13F filings with the SEC.

News

Stay updated on L.M. Kohn & Company with notifications on news.

Account